|
Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion. |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Nkarta |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Pfizer |
Research Funding - Otsuka |
Travel, Accommodations, Expenses - Eisai; Pfizer |
|
|
Consulting or Advisory Role - Pfizer; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Otsuka |
Research Funding - Bayer; Genentech/Roche; Kyowa Hakko Kirin |
|
|
Stock and Other Ownership Interests - Medisix Therapeutics; Nkarta; Unum Therapeutics |
Consulting or Advisory Role - Lion TCR; Medisix Therapeutics |
Patents, Royalties, Other Intellectual Property - Juno Therapeutics; Medisix therapeutics; Nkarta; Unum Therapeutics |
Travel, Accommodations, Expenses - Celgene; GlaxoSmithKline |
|
|
No Relationships to Disclose |